Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
9 participantsStarted 2026-03-01
Plain-language summary
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
Who can participate
Age range50 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient between 50 and 85 years old
* AD diagnosis according to NIA-AA 2011 criteria at a mild to moderate stage :
MMSE score between 14 and 26 (include) positive AD amyloid biomarker
* CDR (clinical dementia rating) score ≥ 1
* Patient with no absolute contraindications for PET or MRI scans
* Consent signed by the patient and study partner
* presence of primary caregiver
* Patient with social security coverage
Exclusion Criteria:
* Brain disease (other than AD) that may cause dementia
* Presence of concomitant pathologies not permitting participation in the study
* Concurrent participation in other research that may influence the testing of the A3D study
* Carrier of a pacemaker, valve prosthesis or other internal magnetic or electronic system, history of neurosurgery or aneurysm surgery, presence of metal fragments in the eyes, brain or marrow, claustrophobia
* PET scan performed in the previous year (research context)
* History of cancer diagnosed within the last 5 years
* Presence of \> 4 brain microbleeds, a single area of superficial siderosis, or evidence of previous macrohaemorrhage assessed by brain MRI scan
* Regular use of corticosteroids or other steroidal anti-inflammatory drugs (e. g. prednisone)
* Presence of an autoimmune disease (e. g. rheumatoid arthritis, systemic lupus erythematosus) with the exception of psoriasis
* Pregnant or breastfeeding woman
* Adults under guardianship or other legal protection, deprived of their liberty b…
What they're measuring
1
number of participants in each group with a clinically significant serious or non-serious AE related to treatment